WHO Grade 2 Meningiomas: Management Dilemmas
8th March, 2026, 08:35 - 09:35
Pacific A
WHO grade 2 meningiomas have heterogenous outcomes and significant variability in management based on surgeon and institution. In this session, we will provide an overview of advances in neuropathology and the molecular biology of meningiomas that are relevant to informing management of these tumors as well as advances in molecular imaging with somatostatin-analogue PET. We will then discuss three cases of anterior cranial fossa meningioma with controversial management and how these advances were applied to guide treatment.
Objectives
At the conclusion of this session, attendees will be able to:
- Identify high risk molecular pathology in WHO grade 2 meningioma.
- Identify when somatostatin-PET imaging can inform WHO grade 2 meningioma treatment.
- Apply molecular pathology and imaging findings to manage anterior cranial fossa meningiomas.
Current Schedule
As a faculty member of this session, you can click on names to email the speaker. Phone numbers are below names
| Speaker | Title | Role | Times |
|---|---|---|---|
| Stephen Magill 415-583-8505 |
Moderator | - | |
| Ramin Morshed 650-823-7511 |
Moderator | - | |
| Jennifer Moliterno Gunel 203-785-2791 |
Meningioma Molecular Neuropathology: Overview of High Risk Molecular Features for the Skull Base Surgeon | Speaker | 8:35 am - 8:50 am |
| Jana Ivanidze 3475141491 |
Advances in DOTATATE-PET Imaging to Inform Meningioma Management | Speaker | 8:50 am - 9:05 am |
| Stephen Magill 415-583-8505 |
Case 1: Anterior Cranial Fossa, WHO Grade 2 Meningioma Management | Speaker | 9:05 am - 9:15 am |
| Ivan El-Sayed 415-353-2206 |
Case 2: Anterior Cranial Fossa, WHO Grade 2 Meningioma Management | Speaker | 9:15 am - 9:25 am |
| Theodore Schwartz 6467343801 |
Case 3: Anterior Cranial Fossa, WHO Grade 2 Meningioma Management | Speaker | 9:25 am - 9:35 am |